Details of the Drug

General Information of Drug (ID: DMMJQSH)

Drug Name

Lanthanum carbonate

Synonyms

Fosrenol; Foznol; Lambda; Lanthanum; Phosphate binding agent, Shire/Johnson Matthey; Project Lambda, Shire/Johnson Matthey

Indication

Disease Entry	ICD 11	Status	REF
Hypophosphatasia	5C64.3	Approved	[1]
------------------------------------------------------------------------------------

Affected Organisms

Humans and other mammals

ATC Code

V03AE03: Lanthanum carbonate

V03AE: Drugs for treatment of hyperkalemia and hyperphosphatemia

V03A: ALL OTHER THERAPEUTIC PRODUCTS

V03: ALL OTHER THERAPEUTIC PRODUCTS

V: VARIOUS

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

457.84

Logarithm of the Partition Coefficient

Not Available

Rotatable Bond Count

0

Hydrogen Bond Donor Count

0

Hydrogen Bond Acceptor Count

9

ADMET Property

Bioavailability: The bioavailability of drug is 0.002% []
Half-life: The concentration or amount of drug in body reduced by one-half in 53 hours [2]
Metabolism: The drug is not metabolised []

Chemical Identifiers

Formula: C3La2O9
IUPAC Name: lanthanum(3+);tricarbonate
Canonical SMILES: C(=O)([O-])[O-].C(=O)([O-])[O-].C(=O)([O-])[O-].[La+3].[La+3]
InChI: InChI=1S/3CH2O3.2La/c3*2-1(3)4;;/h3*(H2,2,3,4);;/q;;;2*+3/p-6
InChIKey: NZPIUJUFIFZSPW-UHFFFAOYSA-H

Cross-matching ID

PubChem CID: 168924
CAS Number: 587-26-8
UNII: 0M78EU4V9H
DrugBank ID: DB06792
TTD ID: D0H1LO
ACDINA ID: D00350

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphate (PHO)	TTHOTF6	NOUNIPROTAC	Modulator	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Lanthanum carbonate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sarecycline	DMLZNIQ	Moderate	Decreased absorption of Lanthanum carbonate due to formation of complexes caused by Sarecycline .	Acne vulgaris [ED80]	[3]
ABT-492	DMJFD2I	Moderate	Decreased absorption of Lanthanum carbonate due to formation of complexes caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[3]
Omadacycline	DMR2J95	Moderate	Decreased absorption of Lanthanum carbonate due to formation of complexes caused by Omadacycline.	Bacterial infection [1A00-1C4Z]	[3]
-----------

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Lanthanum carbonate 1000 mg tablet	1000 mg	Chewable Tablet	Oral
Lanthanum carbonate 500 mg tablet	500 mg	Chewable Tablet	Oral
Lanthanum carbonate 750 mg tablet	750 mg	Chewable Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	Canadian Pharmacists Association.